Dexmedetomidine (DrugBank: Dexmedetomidine)
12 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 2 |
| 4 | 原発性側索硬化症 | 1 |
| 6 | パーキンソン病 | 9 |
| 21 | ミトコンドリア病 | 1 |
| 34 | 神経線維腫症 | 1 |
| 46 | 悪性関節リウマチ | 2 |
| 70 | 広範脊柱管狭窄症 | 6 |
| 113 | 筋ジストロフィー | 1 |
| 212 | 三尖弁閉鎖症 | 1 |
| 215 | ファロー四徴症 | 4 |
| 226 | 間質性膀胱炎（ハンナ型） | 1 |
| 280 | 巨大動静脈奇形（頚部顔面又は四肢病変） | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04391361 (ClinicalTrials.gov) | November 1, 2020 | 13/5/2020 | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;Respiratory Function;Scopolamine | Drug: Scopolamine, atropine, edaravone and dexmedetomidine;Drug: Edaravone | Ruijin Hospital | NULL | Not yet recruiting | 30 Years | 65 Years | All | 30 | Phase 2 | China |
| 2 | EUCTR2018-000142-18-FI (EUCTR) | 09/05/2018 | 08/05/2018 | Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative care | Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE Trade Name: Ketanest-S INN or Proposed INN: ESKETAMINE | Turku University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 4 | Finland |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-000142-18-FI (EUCTR) | 09/05/2018 | 08/05/2018 | Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative care | Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE Trade Name: Ketanest-S INN or Proposed INN: ESKETAMINE | Turku University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 4 | Finland |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02982512 (ClinicalTrials.gov) | May 1, 2017 | 28/11/2016 | Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease | Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease | Dexmedetomidine;Deep Brain Stimulation;Parkinson Disease | Drug: Dexmedetomidine | Clinica Universidad de Navarra, Universidad de Navarra | NULL | Unknown status | 18 Years | N/A | All | 12 | Phase 4 | Spain |
| 2 | ChiCTR-IOR-16010168 | 2016-12-20 | 2016-12-15 | Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation | Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation | Parkinson's Disease | propofol-remifentanyl group:propofol-remifentany infusion for monitored anesthesia care during awake deep brain stimulation surgery;dexmedetomidine group:dexmedetomidine infusion for monitored anesthesia care during awake deep brain stimulation surgery; | West China Hospital, Sichuan University | NULL | Recruiting | 18 | Both | propofol-remifentanyl group:25;dexmedetomidine group:25; | China | ||
| 3 | ChiCTR2000037957 | 2016-12-01 | 2020-09-07 | Clinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's disease | Clinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's disease | Deep brain stimulation in patients with Parkinson's disease | Experimental group:conscious sedation with dexmedetomidine;control group:Pump in normal saline; | Shanghai Jing'an District Central Hospital | NULL | Completed | 45 | 75 | Both | Experimental group:27;control group:9; | China | |
| 4 | EUCTR2016-002680-34-ES (EUCTR) | 20/10/2016 | 05/08/2016 | Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease. | Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease. | Parkinson's disease MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Trade Name: Dexdor Product Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE Other descriptive name: DEXMEDETOMIDINA | Clínica Universidad de Navarra/Universidad de Navarra | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 4 | Spain | ||
| 5 | NCT02256319 (ClinicalTrials.gov) | September 2014 | 30/9/2014 | Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators | Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators | Parkinson's Disease | Drug: Dexmedetomidine;Drug: Propofol | Clinica Universidad de Navarra, Universidad de Navarra | NULL | Completed | 18 Years | N/A | Both | 12 | Phase 4 | Spain |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2014-000868-17-ES (EUCTR) | 26/06/2014 | 17/03/2014 | Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulators | Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulators | Parkinson's disease MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Trade Name: Dexdor Product Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE Other descriptive name: DEXMEDETOMIDINA Trade Name: Propofol-Lipuro Product Name: Propofol-Lipuro INN or Proposed INN: PROPOFOL Other descriptive name: PROPOFOL | Clínica Universidad de Navarra/Universidad de Navarra | NULL | Not Recruiting | Female: yes Male: yes | Spain | ||||
| 7 | NCT01789385 (ClinicalTrials.gov) | February 2013 | 2/2/2013 | Anesthesia for Deep Brain Stimulation | Anesthesia for Deep Brain Stimulation for the Treatment of Parkinsons Disease | Parkinsons Disease | Drug: Dexmedetomidine | Diskapi Teaching and Research Hospital | NULL | Completed | 19 Years | 85 Years | Both | 26 | Phase 4 | Turkey |
| 8 | NCT01721460 (ClinicalTrials.gov) | November 2012 | 30/10/2012 | Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus | Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery | Parkinson's Disease;Deep Brain Stimulation Surgery | Drug: Dexmedetomidine | University of Wisconsin, Madison | NULL | Completed | 18 Years | 85 Years | All | 6 | Phase 4 | United States |
| 9 | NCT00608231 (ClinicalTrials.gov) | January 2008 | 7/1/2008 | Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation | Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation | Parkinson's Disease;Essential Tremor;Dystonia | Drug: Dexmedetomidine Hydrochloride Infusion;Drug: Normal Saline | Vanderbilt University | NULL | Withdrawn | 18 Years | N/A | Both | 0 | Phase 2;Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02053766 (ClinicalTrials.gov) | January 10, 2014 | 31/1/2014 | Anesthesia in Patients With Mitochondrial Disease | Anesthesia in Patients With Mitochondrial Disease | Mitochondrial Diseases | Drug: Sevoflurane;Drug: Dexmedetomidine;Drug: Propofol | The University of Texas Health Science Center, Houston | NULL | Recruiting | N/A | 17 Years | All | 60 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03513757 (ClinicalTrials.gov) | March 4, 2018 | 4/2/2018 | Dexmedetomidine and Propofol for Pediatric MRI Sedation | An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging | Headache;Tumor;Seizure Disorder;Neurofibromatoses;Hydrocephalus;Abdominal Neoplasm;Spine Deformity | Drug: propofol;Drug: Dexmedetomidine;Drug: Glycopyrrolate;Drug: Lidocaine 1% Injectable Solution;Drug: Nitrous Oxide;Drug: Sevoflurane | Medical College of Wisconsin | NULL | Completed | 12 Months | 60 Months | All | 40 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000036316 | 2021-01-01 | 2020-08-22 | Effects of dexmedetomidine on periarticular infiltration analgesia in total knee arthroplasty: a prospective, double-blind, randomized controlled trial | Effects of dexmedetomidine on periarticular infiltration analgesia in total knee arthroplasty: a prospective, double-blind, randomized controlled trial | knee osteoarthritis/ knee rheumatoid arthritis | A:Drug composition of local infiltration around the joint: Ropivacaine ;B:Drug composition of local infiltration around the joint is: Ropivacaine and dexmedetomidine; | West China Hospital, Sichuan University | NULL | Pending | 18 | 80 | Both | A:40;B:40; | China | |
| 2 | ChiCTR2000036164 | 2021-01-01 | 2020-08-21 | Effects of dexmedetomidine on periarticular infiltration analgesia in total hip arthroplasty: a prospective, double-blind, randomized controlled trial | Effects of dexmedetomidine on periarticular infiltration analgesia in total hip arthroplasty: a prospective, double-blind, randomized controlled trial | knee osteoarthritis/ knee rheumatoid arthritis | A:Drug composition of local infiltration around the joint: Ropivacaine ;B:Drug composition of local infiltration around the joint is: Ropivacaine and dexmedetomidine ; | West China Hospital, Sichuan University | NULL | Pending | 18 | 80 | Both | A:40;B:40; | china |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04391855 (ClinicalTrials.gov) | May 10, 2020 | 13/5/2020 | Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Plus Ropivacaine for Pain Relief After Spine Surgery | Effect of Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Sulfate as Adjuncts to the Local Anesthetic on Pain Relief After Spine Surgery | Analgesia;Pain, Postoperative;Spinal Stenosis;Spinal Disease | Drug: Tramadol with ropivacaine;Drug: Dexmedetomidine with ropivacaine;Drug: Magnesium with ropivacaine;Drug: Ropivacaine plus normal saline | Aristotle University Of Thessaloniki | NULL | Recruiting | 18 Years | 80 Years | All | 78 | Phase 4 | Greece |
| 2 | NCT02902380 (ClinicalTrials.gov) | September 27, 2016 | 6/9/2016 | The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery | Spinal Stenosis | Drug: dexmedetomidine group;Drug: control group | Yonsei University | NULL | Completed | 20 Years | 70 Years | All | 52 | N/A | Korea, Republic of | |
| 3 | EUCTR2015-002694-37-FI (EUCTR) | 01/09/2016 | 04/01/2016 | Dexmedetomidine is a drug that is used mainly for sedation in the intensive care unit. Purpose of this study is to determine does Dexmedetomidine infusion provide pain management in the postoperative period and prevent chronic pain. Patients are randomized to receive either placebo or dexmedetomidine infusion. DEXPAIN-study has been approved by Kuopio university hospitals ethics committee. | Dexmedetomidine infusion in pain management during low back surgeryDexmedetomidine is an alpha-2-adrenergic agonist that is used mainly for sedation in the intensive care unit. Alpha-2-adrenoceptors agonists have several beneficial actions in a surgical patient. They decrease symphatetic tone, reduce anesthetic and opioid requirements and cause sedation and analgesia. Pain after low back surgery is intense and can become chronic. We need a new drug to manage pain during postoperative period and to prevent chronic pain.DEXPAIN-study has been approved by Kuopio university hospitals ethics committee. Study is single centered, randomized and placebo-controlled study. A total of 60 patients scheduled for low back surgery will be enrolled in this study. Patients eligibility will be assessed by pre-determined inclusion-exclusion-criteria. Purpose of this study is to determine does Dexmedetomidine infusion provide pain management in the postoperative period and prevent chronic pain. Patients are randomized to receive either placebo or dexmedetomidine infusion. Patients in the dexmedetomidine group receive dexmedetomidine loading dose 1ug/kg for 10 minutes and continuous infusion 1.4 ug/kg/h during surgery and post-anesthesia care unit. Total infusion time will be four hours. Anesthesia is standardized and post-operative pain is treated with patient controlled analgesia made of oxycodone. Questionnaires will be used to assess pain control.Study is scheduled to start as soon as we obtain permission from Finnish Medicines Agency and receive sufficient funding. | Low back pain, Discus prolapse, Spinal stenosis;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Trade Name: Dexmedetomidine Product Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE | Kuopio University hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | Finland | ||||
| 4 | EUCTR2014-003252-31-FI (EUCTR) | 15/05/2015 | 22/04/2015 | Dose-response of dexmedetomidine in patient controlled analgesia in orthopaedic surgery patients | Dose response study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in orthopaedic spine surgery patients - DoserespDex_2.0 | Patients, who are scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation MedDRA version: 17.1;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] | Trade Name: Dexdor INN or Proposed INN: deksmedetomidiini Other descriptive name: DEXMEDETOMIDINE HYDROCHLORIDE Trade Name: Oxanest INN or Proposed INN: oksikodoni Other descriptive name: OXYCODONE HYDROCHLORIDE | University of Turku | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
| 5 | NCT01377623 (ClinicalTrials.gov) | September 2010 | 3/1/2011 | Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion | Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion | Spinal Stenosis;Inflammation | Drug: Dexmedetomidine group;Drug: Placebo group | New York University School of Medicine | Hospira, now a wholly owned subsidiary of Pfizer | Terminated | 18 Years | N/A | All | 66 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00808665 (ClinicalTrials.gov) | June 2009 | 15/12/2008 | Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion | Does Continuous Perioperative Dexmedetomidine Infusion Reduce Time to Discharge in Patients Undergoing Major Lumbar Fusion? A Double-Blind, Placebo-Controlled Study | Spinal Fusion Acquired;Spinal Stenosis;Lesions of Lumbosacral Intervertebral Disc;Spinal Diseases | Drug: Dexmedetomidine;Drug: 0.9% Saline | Vanderbilt University Medical Center | NULL | Completed | 18 Years | 85 Years | All | 68 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01645098 (ClinicalTrials.gov) | August 2011 | 8/6/2012 | Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy | Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: Ketamine;Drug: Dexmedetomidine | Nationwide Children's Hospital | NULL | Completed | N/A | N/A | Male | 53 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00573066 (ClinicalTrials.gov) | May 2004 | 11/12/2007 | Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | Hypoplastic Left Heart;Tetralogy of Fallot;Tricuspid Atresia | Drug: Dexmedetomidine | Athena Zuppa | NULL | Completed | 1 Month | 24 Months | All | 56 | Phase 1 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-IOR-16008571 | 2016-06-06 | 2016-05-31 | Premedication for children with Tetralogy of Fallot | A comparative evalution of varies premedication regimes on children with Tetralogy of Fallot | Tetralogy of Fallot | oral dexmedetomidine:oral dexmedetomidine;oral ketamine:oral ketamine;oral dexmedetomidine mixed with ketamine:oral dexmedetomidine mixed with ketamine; | Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University | NULL | Recruiting | Both | oral dexmedetomidine:20;oral ketamine:20;oral dexmedetomidine mixed with ketamine:20; | China | |||
| 2 | NCT01915277 (ClinicalTrials.gov) | April 2, 2014 | 30/7/2013 | A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics | A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics | Transposition of the Great Arteries;Tetralogy of Fallot;Ventricular Septal Defect | Drug: Dexmedetomidine | HealthCore-NERI | National Heart, Lung, and Blood Institute (NHLBI) | Completed | N/A | 180 Days | All | 119 | Phase 1 | United States |
| 3 | NCT00848393 (ClinicalTrials.gov) | November 2008 | 19/2/2009 | Measures to Lower the Stress Response in Pediatric Cardiac Surgery | Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl (LDF), Low Dose Fentanyl Plus Dexmedetomidine (LDF + Dex) and High Dose Fentanyl (HDF). | Tetralogy of Fallot (TOF);Ventricular Septal Defects (VSD);Atrioventricular Septal Defects (AVSD) | Drug: Fentanyl (High Dose);Drug: Fentanyl (Low Dose);Drug: Fentanyl (Low Dose) + Dexmedetomidine | Nationwide Children's Hospital | NULL | Completed | 1 Month | 3 Years | All | 52 | Phase 2 | United States |
| 4 | NCT00573066 (ClinicalTrials.gov) | May 2004 | 11/12/2007 | Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | Hypoplastic Left Heart;Tetralogy of Fallot;Tricuspid Atresia | Drug: Dexmedetomidine | Athena Zuppa | NULL | Completed | 1 Month | 24 Months | All | 56 | Phase 1 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01195116 (ClinicalTrials.gov) | May 2010 | 13/8/2010 | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: Dexmedetomidine;Drug: Normal Saline | University of Rochester | NULL | Completed | 18 Years | N/A | All | 41 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03076099 (ClinicalTrials.gov) | January 1, 2016 | 6/3/2017 | Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization | Effects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation Embolization | Anesthesia | Drug: Dexmedetomidine;Other: normal saline | Nan Jiang | NULL | Recruiting | 18 Years | 65 Years | All | 30 | N/A | China |
| 2 | NCT02552459 (ClinicalTrials.gov) | September 2015 | 26/5/2015 | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled Study | Arteriovenous Malformation | Drug: Sufentanil;Drug: dexmedetomidine 1;Drug: dexmedetomidine 2;Drug: dexmedetomidine 3 | First Affiliated Hospital, Sun Yat-Sen University | NULL | Recruiting | 18 Years | 65 Years | Both | 120 | Phase 4 | China |